Radiolabeling of new generation magnetic poly(HEMA-MAPA) nanoparticles with 131I and preliminary investigation of its radiopharmaceutical potential using albino Wistar rats

Simple item page
dc.contributor.authorAvcibaşi U.
dc.contributor.authorDemiroǧlu H.
dc.contributor.authorEdiz M.
dc.contributor.authorAkalin H.A.
dc.contributor.authorÖzçalişkan E.
dc.contributor.authorŞenay H.
dc.contributor.authorTürkcan C.
dc.contributor.authorÖzcan Y.
dc.contributor.authorAkgöl S.
dc.contributor.authorAvcibaşi N.
dc.date.accessioned2024-07-22T08:18:55Z
dc.date.available2024-07-22T08:18:55Z
dc.date.issued2013
dc.description.abstractIn this study, N-methacryloyl-l-phenylalanine (MAPA) containing poly(2-hydroxyethylmethacrylate) (HEMA)-based magnetic poly(HEMA-MAPA) nanobeads [mag-poly(HEMA-MAPA)] were radiolabeled with 131I [ 131I-mag-poly(HEMA-MAPA)], and the radiopharmaceutical potential of 131I-mag-poly(HEMA-MAPA) was investigated. Quality control studies were carried out by radiochromatographic method to be sure that 131I binded to mag-poly(HEMA-MAPA) efficiently. In this sense, binding yield of 131I-mag-poly(HEMA-MAPA) was found to be about 95-100%. In addition to this, optimum radiodination conditions for 131I-mag-poly(HEMA- MAPA) were determined by thin-layer radiochromatography studies. In addition to thin-layer radiochromatography studies, lipophilicity (partition coefficient) and stability studies for 131I-mag-poly(HEMA-MAPA) were realized. It was determined that lipophilicities of mag-poly(HEMA-MAPA) and 131I-mag-poly(HEMA-MAPA) were 0.12 ± 0.01 and 1.79 ± 0.76 according to ACD/logP algorithm program, respectively. Stability of the radiolabeled compound was investigated in time intervals given as 0, 30, 60, 180, and 1440 min. It was found that 131I-mag-poly(HEMA-MAPA) existed as a stable complex in rat serum within 60 min. After that, biodistribution and scintigraphy studies were carried out by using albino Wistar rats. It was determined that the most important 131I activity uptake was observed in the breast, the ovary, and the pancreas. Scintigraphy studies well supported biodistribution results. Copyright © 2013 John Wiley & Sons, Ltd.
dc.identifier.DOI-ID10.1002/jlcr.3108
dc.identifier.issn03624803
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/17463
dc.language.isoEnglish
dc.publisherJohn Wiley and Sons Ltd
dc.subjectAlbinism
dc.subjectAnimals
dc.subjectIodine Radioisotopes
dc.subjectIsotope Labeling
dc.subjectMagnetite Nanoparticles
dc.subjectPhenylalanine
dc.subjectPolyhydroxyethyl Methacrylate
dc.subjectRadiopharmaceuticals
dc.subjectRats
dc.subjectRats, Wistar
dc.subjectTissue Distribution
dc.subjectRattus
dc.subjectRattus norvegicus
dc.subjectAmino acids
dc.subjectControlled drug delivery
dc.subjectNanomagnetics
dc.subjectNanostructured materials
dc.subjectNuclear medicine
dc.subject131I
dc.subjectdrug carrier systems
dc.subjectnanobeads
dc.subjectpoly(HEMA)
dc.subjectpoly(HEMA-MAPA)
dc.subjectmag poly(hema mapa) i 131
dc.subjectmedronate technetium tc 99m
dc.subjectradiopharmaceutical agent
dc.subjecttechnetium 99m
dc.subjecttetrofosmin tc 99m
dc.subjectunclassified drug
dc.subject2-hydroxyethylmethacrylate
dc.subjectDrug carrier systems
dc.subjectl-Phenylalanine
dc.subjectNanobeads
dc.subjectPoly((2-hydroxyethylmethacrylate))
dc.subjectPoly((2-hydroxyethylmethacrylate)-N-methacryloyl-l-phenylalanine)
dc.subjectRadiochromatography
dc.subjectThin layers
dc.subjectWistar rat
dc.subjectanimal model
dc.subjectarticle
dc.subjectcontrolled study
dc.subjectdrug binding
dc.subjectdrug distribution
dc.subjectdrug stability
dc.subjectfemale
dc.subjectin vitro study
dc.subjectisotope labeling
dc.subjectlipophilicity
dc.subjectnonhuman
dc.subjectradiochromatography
dc.subjectradioiodination
dc.subjectrat
dc.subjectRats
dc.titleRadiolabeling of new generation magnetic poly(HEMA-MAPA) nanoparticles with 131I and preliminary investigation of its radiopharmaceutical potential using albino Wistar rats
dc.typeArticle

Files

Collections

Scopus Koleksiyonu